Revolutionizing C. difficile Prevention
- September 15, 2025
We’re proud to unveil a non-GMO probiotic solution designed to prevent C. difficile relapse - a scalable, regulator-friendly alternative to donor-derived treatments.
Why this matters:
✅ Proven efficacy: Complete relapse prevention demonstrated in 18+ preclinical studies (mice & hamsters).
✅ Robust IP portfolio: US ‘Composition of Matter’ patent granted, with PCT application underway to secure broad international protection.
✅ Safety & Quality: One QPS/GRAS strain with cGLP toxicology studies, validated stability, and a fully defined mechanism of action.
✅ Flexible applications: Suitable for drug development or as a dietary supplement.
A Breakthrough Opportunity
This unique probiotic platform empowers food and pharmaceutical companies to expand their portfolio with a next-generation solution for gut health and infection control.
📩 To discuss further, contact Dr Simon Cutting at Sporegen (s.cutting@sporegen.com).